Issue №176 · 2026-11-08

Daily Briefing · 2026-11-08

Physicians

Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics won’t enroll more patients in the Phase 3 trial of its Duchenne muscular dystrophy gene therapy Elevidys, a test that was meant to act as confirmatory evidence for an approval in older boys. ...

Endpoints News ↗

Physicians

STAT+: New tumor cases show common gene therapy tool can come with risk

STAT+: New tumor cases show common gene therapy tool can come with risk

New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.

Stat News - Pharma ↗

Physicians

What 20 years in hospital medicine taught me about starting a health tech company

What 20 years in hospital medicine taught me about starting a health tech company

An emergency physician and hospitalist explains how a paperwork problem that followed him across his career became a startup, why he replaced his development team with an AI coding assistant and six lessons for physician

Medical Economics ↗

Pharmacy

Patient-Friendly Simplifications of Outpatient Reports Using Large Language Models via Few-Shot Prompting: Bli

Patient-Friendly Simplifications of Outpatient Reports Using Large Language Models via Few-Shot Prompting: Bli

Background: Effective communication between clinicians and patients plays an important role in the successful delivery of health care. In geriatric medicine, where multimorbidity, polypharmacy, and functional limitations

Journal of Medical Internet Research (JMIR) ↗

Pharmacy

STAT+: Amgen’s Repatha linked to fewer heart attacks

STAT+: Amgen’s Repatha linked to fewer heart attacks

Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…

Stat News - Pharma ↗

Pharmacy

STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more

STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more

Novartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy

Stat News - Pharma ↗

Pharmacy

Gene Therapy Under Scrutiny After Nine Tumor Reports

Gene Therapy Under Scrutiny After Nine Tumor Reports

(MedPage Today) -- Drugmaker Novartis acknowledged Thursday that there have been nine reports of tumors in children treated with its gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy (SMA). Tw

MedPage Today ↗

Physician Assistant

PAs Win State Legislative Races, Bringing Clinical Experience to Public Office

PAs Win State Legislative Races, Bringing Clinical Experience to Public Office

PAs around the country are heeding the call for more clinical voices in elected office. Six PA candidates won state legislative seats in Montana, North Carolina, Vermont, West Virginia, Michigan, and Iowa in the Nov. 3 m

American Academy of PAs (AAPA) News ↗

Nursing

Nurses’ Attitudes and Experiences With Generative AI in Clinical Practice: Qualitative Systematic Review

Nurses’ Attitudes and Experiences With Generative AI in Clinical Practice: Qualitative Systematic Review

Background: The rapid advancement of generative AI (GenAI) holds transformative potential for clinical nursing practice, yet its integration also brings significant risks and uncertainties. Despite growing discourse on A

Journal of Medical Internet Research (JMIR) ↗

Nursing

Nursing students are using AI faster than schools can govern it: Survey

Nursing students are using AI faster than schools can govern it: Survey

Nursing students using AI faster than schools govern it, creating a gap faculty must address with training and clear policies.

Bing News — Nursing Ambient AI ↗

Digital Health

The Big Challenge for AI in Healthcare Comes After Approval

The Big Challenge for AI in Healthcare Comes After Approval

Typically, software placed on the market will undergo changes and updates after its initial release. In the case of healthcare AI, changes can occur, often unexpectedly, even when the developers have not updated the mode

MedCity News ↗

Digital Health

Charities call for safeguards for AI-generated health information

Charities call for safeguards for AI-generated health information

A coalition of 115 charities are calling on for the development of a UK-wide framework for safe AI-generated health information.

Digital Health News ↗

Digital Health

Debunked Episode 31: CVS Health Restructure, AI ROI Report Findings, FTC Warning Letters

Debunked Episode 31: CVS Health Restructure, AI ROI Report Findings, FTC Warning Letters

In the latest episode of the Debunked podcast, MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, Managing Partner of Health Innovation Pitch, talked about a new report by Bessemer Venture Partners assessing

MedCity News ↗

Digital Health

Correction: A Machine Learning–Based Model to Predict Overactive Bladder Risk Among US Women: Evidence From th

Correction: A Machine Learning–Based Model to Predict Overactive Bladder Risk Among US Women: Evidence From th

In "A Machine Learning-Based Model to Predict Overactive Bladder Risk Among US Women: Evidence From the National Health and Nutrition Examination Survey 2011-2018" [1], the authors noted the following corrections. First,

JMIR Medical Informatics ↗

Health OS

Mayo Clinic Platform launches AI-driven clinical decision support tool

Mayo Clinic Platform launches AI-driven clinical decision support tool

Beginning in November, eligible clinicians will have access to two key capabilities: a specialty-specific chat that covers more than 35 specialties and 22 clinical calculators available via chat or voice dictation.

Fierce Healthcare ↗